X0304 4 2011-10-14 1 0000873364 CEPHALON INC CEPH 0001483588 Aragues Alain 41 MOORES ROAD FRAZER PA 19355 0 1 0 0 Exec VP, President Europe Common Stock 2011-10-14 4 D 0 42275 D 0 D Non-Qualified Stock Option 64.62 2011-10-14 4 D 0 25000 D 2006-02-01 2012-02-01 Common Stock 25000 0 D Non-Qualified Stock Option 48.06 2011-10-14 4 D 0 300 D 2008-12-16 2014-12-16 Common Stock 300 0 D Non-Qualified Stock Option 51.08 2011-10-14 4 D 0 4300 D 2009-12-01 2015-12-01 Common Stock 4300 0 D Non-Qualified Stock Option 71.07 2011-10-14 4 D 0 4300 D 2010-12-19 2016-12-19 Common Stock 4300 0 D Non-Qualified Stock Option 76.11 2011-10-14 4 D 0 5200 D 2011-12-13 2017-12-13 Common Stock 5200 0 D Non-Qualified Stock Option 73.25 2011-10-14 4 D 0 5200 D 2012-12-11 2018-12-11 Common Stock 5200 0 D Non-Qualified Stock Option 59.03 2011-10-14 4 D 0 15000 D 2013-07-30 2019-07-30 Common Stock 15000 0 D Non-Qualified Stock Option 56.07 2011-10-14 4 D 0 15000 D 2013-12-02 2019-12-02 Common Stock 15000 0 D Incentive Stock Option 63.11 2011-10-14 4 D 0 6336 D 2014-12-16 2020-12-16 Common Stock 6336 0 D Non-Qualified Stock Option 63.11 2011-10-14 4 D 0 43664 D 2014-12-16 2020-12-16 Common Stock 43664 0 D Common Stock was converted pursuant to the Agreement and Plan of Merger, dated as of May 1, 2011, among Teva Pharmaceutical Industries Ltd., Copper Acquisition Corp. and Cephalon, Inc. (the "Merger Agreement") into the right to receive the Merger Consideration (as defined in the Merger Agreement) of $81.50 per share in cash. Includes 19,950 shares of Restricted Stock with certain vesting restrictions, which restrictions lapsed under the terms of the Merger Agreement at the Effective Time of the Merger. Options were canceled at the Effective Time of the Merger pursuant to the terms of the Merger Agreement in exchange for a cash payment for each share subject to the option equal to the difference between the Merger Consideration of $81.50 per share and the exercise price of the option. Reflects four-year anniversary from date of grant. Options vest 25% on each anniversary of grant and expire ten years from date of grant. Carolyn S. Iosca, Attorney-in-Fact For: Alain Aragues 2011-10-17